New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most

Health
By Rebecca Robbins and Stephanie Nolen from NYT Health https://ift.tt/uZ3vhKH
via IFTTT Sickle Cell Anemia, Genetic Engineering, Blood, Genetics and Heredity, Income Inequality, Bone Marrow, Drugs (Pharmaceuticals), Therapy and Rehabilitation, Developing Countries, Crispr (DNA), Transplants, Stem Cells, your-feed-science, your-feed-healthcare There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda